Track market-moving stories before they get noisy

Canada Pension Plan Investment Board purchased a new position in CONMED Corporation (NYSE:CNMD – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 13,800 shares of the company’s stock, valued at approximately $452,000.

Other institutional investors also recently modified their holdings of the company. Kestra Advisory Services LLC bought a new position in CONMED during the fourth quarter worth $26,000. Kelleher Financial Advisors bought a new position in shares of CONMED in the 3rd quarter worth about $28,000. Aster Capital Management DIFC Ltd lifted its stake in shares of CONMED by 409.2% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 723 shares of the company’s stock valued at $29,000 after purchasing an additional 581 shares during the period. Versant Capital Management Inc boosted its position in shares of CONMED by 210.8% during the 2nd quarter. Versant Capital Management Inc now owns 1,125 shares of the company’s stock valued at $37,000 after purchasing an additional 763 shares in the last quarter. Finally, Quarry LP grew its stake in CONMED by 244.8% during the third quarter. Quarry LP now owns 869 shares of the company’s stock worth $41,000 after purchasing an additional 617 shares during the period.

CONMED Stock Performance CNMD opened at $49.59 on Thursday. CONMED Corporation has a 1-year low of $31.44 and a 1-year high of $56.63. The company has a market cap of $1.49 billion, a price-to-earnings ratio of 26.80, a PEG ratio of 2.24 and a beta of 0.90. The company’s fifty day moving average price is $44.40 and its two-hundred day moving average price is $39.96. The company has a current ratio of 1.48, a quick ratio of 0.69 and a debt-to-equity ratio of 0.63.

CONMED (NYSE:CNMD – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.27. CONMED had a net margin of 4.12% and a return on equity of 14.31%. The firm had revenue of $343.49 million during the quarter, compared to analysts’ expectations of $337.60 million. During the same period last year, the company earned $1.15 earnings per share. The business’s revenue was up .3% on a year-over-year basis. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. On average, analysts expect that CONMED Corporation will post 4.54 EPS for the current fiscal year. Analyst Upgrades and Downgrades Several brokerages have issued reports on CNMD. Wells Fargo & Company boosted their price target on CONMED from $39.00 to $46.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. Needham & Company LLC reiterated a “hold” rating on shares of CONMED in a research note on Monday, July 13th. Weiss Ratings raised shares of CONMED from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, August 5th. BMO Capital Markets assumed coverage on shares of CONMED in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $36.00 price target for the company. Finally, Piper Sandler reiterated a “neutral” rating and set a $45.00 price objective (up from $39.00) on shares of CONMED in a report on Thursday, July 30th. Six equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $41.40.

Get Our Latest Stock Report on CONMED

About CONMED (Free Report)

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.

Further Reading Five stocks we like better than CONMED Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real? GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test Want to see what other hedge funds are holding CNMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CONMED Corporation (NYSE:CNMD – Free Report).

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.

A month has gone by since the last earnings report for Conmed (CNMD - Free Report) . Shares have added about 7.1% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Conmed due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for CONMED Corporation before we dive into how investors and analysts have reacted as of late.

CONMED’s Q2 Earnings and Revenues Beat Estimates, Gross Margin ExpandsCONMEDposted adjusted earnings per share of $1.38 for the second quarter of 2026, up 20% year over year. The figure beat the Zacks Consensus Estimate by 25.5%.

The adjustments include costs related to legal matters and contingent consideration fair value adjustments, among others.

GAAP EPS for the quarter was 77 cents, up 11.6% from the year-ago period’s EPS of 69 cents.

CNMD's Organic Sales Gain MomentumCNMD’s second-quarter revenues of $343.5 million increased 0.3% year over year and beat the consensus estimate by 1.9%. International strength and growth across the company’s key AirSeal, Buffalo Filter and BioBrace platforms supported the quarter.

At constant currency, total revenues declined 0.5% year over year. However, excluding sales tied to CONMED’s strategic exit from certain gastroenterology product offerings, organic constant-currency revenues increased 6%.

Domestic sales totaled $175.4 million, down 8% on a reported basis. Excluding the GI exits, domestic organic revenues rose 2.5%. International sales reached $168.1 million, up 10.8% on a reported basis and 8.9% at constant currency. International organic constant-currency growth was 9.9%.

CONMED's Orthopedic Revenues IncreaseOrthopedic Surgery revenues totaled $152.3 million, up 8.2% year over year on a reported basis and 6.8% at constant currency. International orthopedic revenues advanced 10.8% at constant exchange rates, reflecting broad-based growth across major regions.

Domestic orthopedic sales were nearly flat and fell short of management’s expectations. Nonetheless, the company continued to strengthen its U.S. commercial organization. BioBrace was a major contributor, supported by adoption across orthopedic and foot-and-ankle procedures, particularly rotator cuff repair.

CNMD's General Surgery Business ImprovesGeneral Surgery revenues were $191.2 million, down 5.2% on a reported basis and 5.6% at constant currency. The decline reflected the impact of the GI portfolio exits. On an organic constant-currency basis, General Surgery sales increased 5.3%.

AirSeal and Buffalo Filter led the underlying growth. AirSeal sales increased across capital and single-use products and improved sequentially, but growth remained below management’s expectations. CONMED expects AirSeal trends to improve during the second half of 2026, but at a slower rate than previously assumed.

Direct smoke evacuation sales exceeded the company’s long-term expectation of high-single-digit to low-double-digit growth. This more than offset a modest decline in original equipment manufacturer smoke evacuation sales.

The company continues to prioritize its direct Buffalo Filter portfolio, which carries a stronger margin profile and brings CONMED closer to customers. Management also highlighted early commercial traction in Europe, Canada and Australia, along with expanding U.S. legislation requiring surgical smoke evacuation systems.

CONMED’s Margin AnalysisIn the quarter under review, CNMD’s adjusted gross profit increased 5.6% year over year to $204.4 million. The adjusted gross margin expanded 300 basis points (bps) to 59.5%. The improvement included an $8.5 million benefit from tariff refunds, which contributed nearly 250 bps to the year-over-year expansion.

In the quarter under review, CNMD’s reported gross profit increased 4.9% year over year to $197.5 million. The gross margin expanded 250 bps to 57.5%.

Selling & administrative expenses increased 7% year over year to $145.6 million. Research and development expenses rose 9.6% year over year to $15.5 million. Total operating expenses of $161.1 million increased 7.3% on a year-over-year basis.

Total operating profit totaled $36.4 million, reflecting a 4.6% decrease from the year-ago quarter. The operating margin contracted 50 bps to 10.6%.

CNMD’s Financial PositionThe company exited the second quarter with cash and cash equivalents of $37.3 million compared with $35 million a year ago.

Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $50.6 million compared with $70.7 million a year ago.

CONMED’s GuidanceCNMD has updated its outlook for 2026.

For 2026, total reported revenues are expected to be in the range of $1,358 million-$1,373 million compared with the previous guidance of $1,350 million-$1,375 million. This represents a reported revenue decline of 1.2-0.1% year over year.

Organic constant-currency revenue growth is expected to be 5-6% compared with the prior projection of 5-6.5%. The revised outlook reflects second-quarter performance and a more measured pace of sequential growth improvement in the second half of 2026.

The company now expects adjustedearnings per share PS for 2026 in the range of $4.48-$4.60, up from its previous guidance of $4.30-$4.45. The raised outlook reflects better-than-expected second-quarter results, a lower projected headwind from the GI product exits and a higher contribution from share repurchases. These benefits are expected to be partly offset by higher interest expenses and an increased tax-rate assumption.

CONMED expects third-quarter revenues to be in the range of $334 million-$339 million. Organic constant-currency growth is projected to be between 6.4% and 7.6%, excluding anticipated GI revenues of $3 million-$3.6 million and an approximately 10-basis-point foreign currency impact. Adjusted earnings per share is expected to be between 98 cents and $1.03.

How Have Estimates Been Moving Since Then?It turns out, estimates review have trended downward during the past month.

VGM ScoresCurrently, Conmed has a average Growth Score of C, however its Momentum Score is doing a bit better with a B. Charting a somewhat similar path, the stock was allocated a grade of A on the value side, putting it in the top 20% for value investors.

Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Conmed has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Key Takeaways CONMED delivered 6% organic sales growth in Q2, with broad momentum across its continuing portfolio.Buffalo Filter is gaining from smoke-free OR laws, while BioBrace sees growing surgeon adoption and retention.AirSeal growth is slowing, while tariffs are expected to create a 35 cent EPS headwind in 2026. CONMED Corporation (CNMD - Free Report) is well positioned for growth on the back of rising adoption of its high-margin, differentiated platforms like AirSeal, Buffalo Filter and BioBrace. The company’s long-term prospects seem good as robotic procedure volume rises, coupled with the expanding penetration of Ambulatory Surgery Centers. Improving supply-chain bottlenecks should drive top and bottom-line growth.

CONMED is facing tariff headwinds that are unfavorably impacting its earnings per share (EPS) and revenue expansion. Higher operating expense investments remain a concern.

Shares of this Zacks Rank #3 (Hold) company have gained 24.2% in the year-to-date period, outperforming the industry’s 5.8% increase and the S&P 500 Index’s 13.3% rise.

Image Source: Zacks Investment Research

CONMED, a renowned global medical products manufacturer specializing in surgical instruments and devices, has a market capitalization of $1.51 billion. The company projects 4.8% earnings growth over the next five years.

The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.30%.

Factors Favoring CNMD StockCore Portfolio Is Returning to Healthy Organic Growth: CONMED delivered 6% organic sales growth in the second quarter of 2026, modestly above the high end of its previous expectation, despite reported revenues rising only 0.3% due to portfolio exits and currency. General Surgery grew 5.3% organically, while Orthopedic Surgery increased 6.8%, demonstrating broad-based momentum across the continuing portfolio.

International orthopedic sales were particularly strong, rising 10.8%. Management remains confident in achieving at least 5% organic constant-currency growth in 2026, while expecting sequential improvement during the second half. This suggests that the business is likely to report healthier returns in the next couple of quarters as CONMED completes its portfolio optimization.

Buffalo Filter Benefits From Regulatory Tailwinds: Buffalo Filter offers CONMED a potentially durable growth opportunity as surgical smoke evacuation gains regulatory momentum. Direct smoke evacuation sales exceeded the company's longer-term high-single-digit to low-double-digit growth target in the second quarter, more than offsetting declines in the OEM portfolio.

Importantly, 22 U.S. states now have smoke-free operating-room laws covering approximately 57% of the U.S. population, while more than 10 additional states have pending legislation. Michigan and Maryland recently added requirements, creating a multiyear adoption runway. CONMED is also seeing early traction internationally and expects its next-generation PlumeSafe X5 to strengthen penetration in ambulatory and outpatient settings.

Biobrace and Orthopedic Soft-Tissue Repair Can Support Sustained Growth: BioBrace is emerging as another differentiated growth franchise, particularly in rotator cuff repair, where approximately 1 million procedures are performed annually in the United States and re-tear rates remain significant. CONMED cites a 94% healing rate among high-risk patients using BioBrace augmentation, supported by more than 30 published studies and updated AAOS guidelines recommending augmentation.

The one-year-old BioBrace RC product is also gaining traction because it simplifies and standardizes augmentation, encouraging repeat utilization. Management noted increasing new-user adoption and durable retention among surgeons who gain experience with the product. These dynamics could create a recurring growth engine as BioBrace penetrates a large unmet clinical need.

Challenges Facing CNMD StockAirSeal Growth Is Moderating Relative to Earlier Expectations: Although AirSeal remained the top contributor to General Surgery growth in the second quarter, its performance was below management's expectations. The company now expects growth to improve in the second half of 2026, but at a slower pace than previously anticipated, prompting a more measured outlook.

This matters because AirSeal is a key component of CONMED's growth thesis, and a slower adoption curve could delay the benefits expected from robotic surgery, laparoscopic procedures and ASC expansion. Management continues to believe the franchise can generate high-single-digit to low-double-digit long-term growth, but the near-term deceleration highlights execution and adoption risks even within one of the company's highest-priority growth platforms.

Tariffs Remain a Meaningful Earnings Headwind Despite Refund: CONMED’s second-quarter EPS benefited materially from a 21-cent-per-share tariff refund, creating a risk that investors may overestimate the sustainability of the quarter’s earnings strength. Management noted that the refund was related to tariffs paid in 2025, while the company continues to expect a roughly 35-cent-per-share EPS headwind from tariffs in 2026.

Excluding the refund, second-quarter adjusted operating margin was essentially flat year over year, underscoring that underlying profitability was less robust than the headline 250-basis-point margin expansion suggested. As a result, future earnings growth will need to be driven by organic sales growth, product mix, and operating efficiencies instead of temporary tariff benefits.

Estimate TrendCONMED is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has improved 3.7% to $4.54 per share.

The Zacks Consensus Estimate for third-quarter 2026 revenues and EPS is pegged at $336.8 million and $1.00, respectively, suggesting a decline of 0.3% and 7.4% from the year-ago reported numbers.

Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

Key Takeaways CONMED raised 2026 adjusted EPS guidance to $4.48-$4.60 after better-than-expected second-quarter results.Second-quarter adjusted EPS rose 20% as organic constant-currency revenue excluding gastroenterology grew 6%.CNMD narrowed its organic growth outlook to 5-6% as higher interest costs and lower cash flow weigh on upside. CONMED Corporation (CNMD - Free Report) raised its 2026 adjusted earnings outlook after a better-than-expected second quarter, testing whether stronger execution can translate into more durable earnings momentum.

The revision comes with a more measured organic growth outlook and higher expected financing costs. That mix keeps the focus on margins, core-platform execution and cash generation through the second half.

CONMED Lifts Its 2026 Earnings ExpectationsCONMED now expects 2026 adjusted earnings of $4.48-$4.60 per share, up from $4.30-$4.45. The increase reflects better-than-expected second-quarter results, a lower projected earnings headwind from the gastroenterology product exits and a higher contribution from share repurchases.

Higher interest expense and an increased tax-rate assumption partly offset those benefits. The revised range therefore depends on operating gains holding up despite a less favorable financing backdrop.

CNMD’s Second Quarter Provides the FoundationSecond-quarter adjusted earnings rose 20% year over year to $1.38 per share and beat the Zacks Consensus Estimate by 25.5%. Revenues reached $343.5 million, up 0.3%, and exceeded the consensus mark by 1.9%. Organic constant-currency revenues excluding gastroenterology increased 6%.

Stryker Corporation (SYK - Free Report) is a relevant medtech peer because its portfolio spans MedSurg, Neurotechnology and Orthopaedics. Medtronic plc (MDT - Free Report) also provides useful industry context through technologies that include surgical robotics and surgical tools.

CONMED’s Margin Expansion Adds Earnings LeverageAdjusted gross margin reached 59.5% in the second quarter, up 300 basis points year over year. An $8.5 million tariff refund accounted for about 250 basis points of the increase.

Excluding that benefit, adjusted gross margin still improved 50 basis points, helped by favorable product mix and foreign currency. Reported gross margin rose 250 basis points to 57.5%, reinforcing that the quarter’s margin improvement was not solely refund-driven.

CNMD’s Second-Half Growth Path Remains MeasuredManagement now expects 2026 organic constant-currency revenue growth of 5%-6%, compared with its prior 5%-6.5% outlook. The lower top end reflects a more measured pace of sequential growth improvement in the second half.

For the third quarter, CONMED expects organic constant-currency growth of 6.4%-7.6%, excluding anticipated gastroenterology revenues of $3 million-$3.6 million and an approximately 10-basis-point foreign currency impact. Adjusted earnings are projected at 98 cents to $1.03 per share.

CONMED’s Financial Headwinds Limit the UpsideThe financing picture remains a constraint. Expected 2026 adjusted interest expense increased to about $33 million from the prior $25-$27 million range following the company’s debt refinancing.

Free cash flow guidance also fell to about $115 million from roughly $125 million, partly reflecting inventory and working-capital needs. Sustained execution across AirSeal, Buffalo Filter and BioBrace will matter more if CONMED is to convert higher earnings expectations into stronger cash generation.

CNMD’s Signals Reflect Improving but Mixed MomentumThe raised earnings outlook improves the near-term fundamental picture, but the narrower organic growth range and higher financing costs keep the setup mixed. The stock’s prospects still depend on consistent execution across core platforms, margins and working capital.

CNMD currently carries a Zacks Rank #3 (Hold), along with a VGM Score of B, Value Score of A, Growth Score of C and Momentum Score of C. The Value Score signals relative strength on valuation measures, while the C grades for Growth and Momentum are more neutral. Likewise, Stryker and Medtronic also carry a Zacks Rank of 3. With a Zacks Rank #3, the combined signals support a measured stance rather than a clear near-term buy signal. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

California State Teachers Retirement System lifted its stake in shares of CONMED Corporation (NYSE: CNMD) by 38.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,340 shares of the company's stock after acquiring an additional 10,845 shares during the

Key Takeaways CONMED's Q2 adjusted EPS rose 20% to $1.38, while revenues edged up 0.3% to $343.5 million.International organic sales grew 9.9%, led by strength in AirSeal, Buffalo Filter and BioBrace.CONMED raised 2026 adjusted EPS guidance to $4.48-$4.60 as gross margin expanded 300 basis points. CONMED Corporation (CNMD - Free Report) posted adjusted earnings per share (EPS) of $1.38 for the second quarter of 2026, up 20% year over year. The figure beat the Zacks Consensus Estimate by 25.5%.

The adjustments include costs related to legal matters and contingent consideration fair value adjustments, among others.

GAAP EPS for the quarter was 77 cents, up 11.6% from the year-ago period’s EPS of 69 cents.

CNMD's Organic Sales Gain MomentumCNMD’s second-quarter revenues of $343.5 million increased 0.3% year over year and beat the consensus estimate by 1.9%. International strength and growth across the company’s key AirSeal, Buffalo Filter and BioBrace platforms supported the quarter.

Shares of CNMD gained 6.3 in today’s pre-market trading. In the year-to-date period, shares of the company gained 6.4% compared with the industry’s 3.3% growth. The S&P 500 increased 8.1% in the same time frame.

At constant currency, total revenues declined 0.5% year over year. However, excluding sales tied to CONMED’s strategic exit from certain gastroenterology product offerings, organic constant-currency revenues increased 6%.

Domestic sales totaled $175.4 million, down 8% on a reported basis. Excluding the GI exits, domestic organic revenues rose 2.5%. International sales reached $168.1 million, up 10.8% on a reported basis and 8.9% at constant currency. International organic constant-currency growth was 9.9%.

Image Source: Zacks Investment Research

CONMED's Orthopedic Revenues IncreaseOrthopedic Surgery revenues totaled $152.3 million, up 8.2% year over year on a reported basis and 6.8% at constant currency. International orthopedic revenues advanced 10.8% at constant exchange rates, reflecting broad-based growth across major regions.

Domestic orthopedic sales were nearly flat and fell short of management’s expectations. Nonetheless, the company continued to strengthen its U.S. commercial organization. BioBrace was a major contributor, supported by adoption across orthopedic and foot-and-ankle procedures, particularly rotator cuff repair.

CNMD's General Surgery Business ImprovesGeneral Surgery revenues were $191.2 million, down 5.2% on a reported basis and 5.6% at constant currency. The decline reflected the impact of the GI portfolio exits. On an organic constant-currency basis, General Surgery sales increased 5.3%.

AirSeal and Buffalo Filter led the underlying growth. AirSeal sales increased across capital and single-use products and improved sequentially, but growth remained below management’s expectations. CONMED expects AirSeal trends to improve during the second half of 2026, but at a slower rate than previously assumed.

Direct smoke evacuation sales exceeded the company’s long-term expectation of high-single-digit to low-double-digit growth. This more than offset a modest decline in original equipment manufacturer smoke evacuation sales.

The company continues to prioritize its direct Buffalo Filter portfolio, which carries a stronger margin profile and brings CONMED closer to customers. Management also highlighted early commercial traction in Europe, Canada and Australia, along with expanding U.S. legislation requiring surgical smoke evacuation systems.

CONMED’s Margin AnalysisIn the quarter under review, CNMD’s adjusted gross profit increased 5.6% year over year to $204.4 million. The adjusted gross margin expanded 300 basis points (bps) to 59.5%. The improvement included an $8.5 million benefit from tariff refunds, which contributed nearly 250 bps to the year-over-year expansion.

In the quarter under review, CNMD’s reported gross profit increased 4.9% year over year to $197.5 million. The gross margin expanded 250 bps to 57.5%.

Selling & administrative expenses increased 7% year over year to $145.6 million. Research and development expenses rose 9.6% year over year to $15.5 million. Total operating expenses of $161.1 million increased 7.3% on a year-over-year basis.

Total operating profit totaled $36.4 million, reflecting a 4.6% decrease from the year-ago quarter. The operating margin contracted 50 bps to 10.6%.

CNMD’s Financial PositionThe company exited the second quarter with cash and cash equivalents of $37.3 million compared with $35 million a year ago.

Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $50.6 million compared with $70.7 million a year ago.

CONMED’s GuidanceCNMD has updated its outlook for 2026.

For 2026, total reported revenues are expected to be in the range of $1,358 million-$1,373 million compared with the previous guidance of $1,350 million-$1,375 million. This represents a reported revenue decline of 1.2-0.1% year over year.

Organic constant-currency revenue growth is expected to be 5-6% compared with the prior projection of 5-6.5%. The revised outlook reflects second-quarter performance and a more measured pace of sequential growth improvement in the second half of 2026.

The company now expects adjusted EPS for 2026 in the range of $4.48-$4.60, up from its previous guidance of $4.30-$4.45. The raised outlook reflects better-than-expected second-quarter results, a lower projected headwind from the GI product exits and a higher contribution from share repurchases. These benefits are expected to be partly offset by higher interest expenses and an increased tax-rate assumption.

CONMED expects third-quarter revenues to be in the range of $334 million-$339 million. Organic constant-currency growth is projected to be between 6.4% and 7.6%, excluding anticipated GI revenues of $3 million-$3.6 million and an approximately 10-basis-point foreign currency impact. Adjusted EPS is expected to be between 98 cents and $1.03.

Our Take on CNMDCONMED exited the second quarter of 2026 with better-than-expected earnings and revenues. Organic constant-currency sales growth of 6% reflected gains across both Orthopedic Surgery and General Surgery, supported by continued momentum in AirSeal, Buffalo Filter and BioBrace. The completion of the GI portfolio exit should allow the company to sharpen its focus on these core growth platforms.

AirSeal continues to benefit from opportunities in robotic and laparoscopic procedures, although second-quarter growth was below management’s expectations. Buffalo Filter remains well positioned to gain from expanding smoke-evacuation legislation and international adoption, while BioBrace continues to see traction in rotator cuff repair and other orthopedic procedures. Improved supply-chain execution, including lower backorders and stronger service levels, should also support more consistent operating performance.

However, challenges remain. The GI exit continues to weigh on reported revenues, while AirSeal’s growth outlook for the second half is lower than previously assumed. Domestic orthopedic sales were nearly flat, and modest weakness in the OEM smoke-evacuation business also pressured General Surgery. Moreover, higher interest expenses following the debt refinancing may limit earnings growth. Despite these headwinds, CONMED raised its adjusted earnings outlook for 2026 and continues to expect organic constant-currency growth of 5-6%.

CONMED’s Zacks Rank & Stocks to ConsiderCNMD currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the broader medical space are McKesson (MCK - Free Report) , Phibro Animal Health (PAHC - Free Report) andCardinal Health (CAH - Free Report) .

McKesson carries a Zacks Rank #2 (Buy) at present and has an estimated long-term growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.09%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

McKesson shares have gained 8.8% against the industry’s 12.7% decline in the year-to-date period.

Phibro Animal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.25%.

Phibro Animal Health stock has climbed 44.2% against the industry’s 17.1% decline in the year-to-date period.

Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.

Cardinal Health’s shares have lost 2.6% compared with the industry’s 3.1% decline in the year-to-date period.

Med-tech stock Conmed dips ahead of big Q4 report...opportunity?CONMED NYSE: CNMD reported second-quarter 2026 net sales of $343.5 million, up 0.3% on a reported basis but down 0.5% in constant currency. Organic sales, which exclude the company’s exited gastroenterology product offerings, rose 6% year over year and modestly exceeded management’s expectations.

Adjusted diluted earnings per share increased 20% year over year to $1.38, compared with $1.15 in the prior-year period. The result included a $0.21-per-share benefit from tariff refunds that had not been included in the company’s guidance. Excluding that benefit, earnings still exceeded the high end of CONMED’s prior guidance by about $0.03 per share, President and CEO Pat Beyer said.

Get CONMED alerts:

“We were pleased to deliver strong financial performance in the second quarter,” Beyer said, pointing to organic growth in both the general surgery and orthopedic surgery businesses.

General Surgery Growth Led by AirSeal and Buffalo Filter General surgery organic sales increased 5.3%, with mid-single-digit growth in the U.S. and high-single-digit international growth. AirSeal, CONMED’s advanced insufflation platform, and Buffalo Filter, its smoke-evacuation platform, were the principal contributors.

AirSeal sales grew in both capital equipment and single-use products, and trends improved sequentially from the first quarter. However, Beyer said growth was below the company’s expectations. CONMED now expects AirSeal growth to improve in the second half of 2026, though at a slower pace than previously assumed in guidance.

The company maintained its long-term view that AirSeal can grow at a high-single-digit to low-double-digit rate, citing its use in robotic and laparoscopic procedures as well as expansion opportunities in ambulatory surgery centers, international markets and U.S. laparoscopy. CONMED estimates AirSeal is used in only 6% to 7% of more than 3 million laparoscopic procedures performed annually in the United States.

CONMED also announced that its AirSeal Robotic Solution is now indicated for use with Intuitive’s 8mm hex cannulas, in addition to the existing indication for 8mm round cannulas. The hex cannulas were introduced with the da Vinci 5 system and are compatible across Intuitive’s X, Xi and da Vinci 5 multi-port platforms. Beyer said the expanded indication was already incorporated into the company’s outlook.

Buffalo Filter’s direct smoke-evacuation portfolio delivered year-over-year growth above the company’s long-term expectation of high-single-digit to low-double-digit growth, more than offsetting modest declines in its OEM smoke-evacuation business. CONMED said it is prioritizing direct sales because of closer customer relationships and a stronger margin profile.

The company cited legislative support for surgical smoke evacuation, including recently enacted laws in Michigan and Maryland. CONMED said 22 states now have smoke-free operating-room laws, covering about 57% of the U.S. population, while more than 10 additional states have pending legislation.

Orthopedics Posts International Strength Orthopedic surgery sales increased 6.8%, driven by 10.8% international growth, including particular strength in Asia-Pacific and Europe, the Middle East and Africa. U.S. orthopedic sales were essentially flat and below expectations.

Beyer said the domestic orthopedic business had undertaken strategic actions to strengthen its commercial organization during the quarter, which temporarily affected growth. He said the U.S. team is “back on offense” and positioned to return to growth.

BioBrace, CONMED’s reinforced bioinductive implant, was a leading contributor to orthopedic growth. The product is being used across orthopedic and foot-and-ankle procedures, particularly rotator cuff repairs. Beyer cited CONMED’s clinical data and updated American Academy of Orthopaedic Surgeons guidelines supporting augmentation in rotator cuff repair as factors supporting adoption.

The company said BioBrace RC, launched one year ago to streamline use of the implant in rotator cuff procedures, has generated increasing new-user adoption and repeat use among surgeons.

Margins, Cash Flow and Debt Refinancing Adjusted gross profit rose 5.6%, while adjusted gross margin expanded 300 basis points to 59.5%. The tariff refund accounted for approximately 250 basis points of margin improvement. Excluding the refund, adjusted gross margin increased 50 basis points, aided by product mix and foreign currency.

Adjusted operating margin was 18.2%, compared with 15.7% a year earlier. Adjusted net income was $41.7 million, compared with $35.6 million in the prior-year quarter. Free cash flow rose 46% to $34.2 million. Cash totaled $37.3 million at June 30, while total debt obligations were $834.2 million. CONMED’s leverage ratio was 2.9 times at quarter-end. During June, CONMED secured a new $450 million senior secured term loan facility maturing in 2030. It used the proceeds, along with borrowings under its revolving credit facility, to repurchase $645.2 million of convertible notes for $637.2 million. The notes had been scheduled to mature in June 2027.

The company also repurchased about 1 million shares for $43.7 million during the first half and continues to expect approximately $61.8 million in full-year share repurchases.

Guidance Updated for 2026 CONMED narrowed its expected organic constant-currency sales growth range to 5% to 6%, from 5% to 6.5%. Beyer said the company reaffirmed confidence in achieving at least 5% growth, but adopted a more measured expectation for improvement in the second half because of the AirSeal outlook.

The company raised its full-year adjusted EPS forecast to $4.48 to $4.60 from $4.30 to $4.45. CFO John Gallagher said the increase reflected the tariff refund, better-than-expected second-quarter operations, a smaller expected headwind from the GI exit and share repurchases. Those factors were partly offset by higher expected interest expense and a higher tax-rate assumption.

CONMED now expects adjusted interest expense of about $33 million for 2026, compared with its earlier forecast of $25 million to $27 million. It reduced its free-cash-flow outlook to approximately $115 million from approximately $125 million, primarily due to working capital, interest expense and tax-rate changes.

For the third quarter, CONMED forecast GAAP net sales of $334 million to $339 million, organic constant-currency growth of 6.4% to 7.6%, and adjusted EPS of $0.98 to $1.03.

About CONMED (NYSE:CNMD)CONMED Corporation NYSE: CNMD is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company's product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in CONMED Right Now?Before you consider CONMED, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CONMED wasn't on the list.

While CONMED currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

For the quarter ended June 2026, Conmed (CNMD - Free Report) reported revenue of $343.49 million, up 0.3% over the same period last year. EPS came in at $1.38, compared to $1.15 in the year-ago quarter.

The reported revenue represents a surprise of +1.85% over the Zacks Consensus Estimate of $337.24 million. With the consensus EPS estimate being $1.10, the EPS surprise was +25.46%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Conmed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Geographic Revenue- International: $168.1 million versus $153.69 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.8% change.Geographic Revenue- Domestic: $175.4 million compared to the $183.55 million average estimate based on two analysts. The reported number represents a change of -8% year over year.Net Sales- Single-use Products: $295.1 million versus the two-analyst average estimate of $286.83 million. The reported number represents a year-over-year change of -0.9%.Net Sales- General Surgery: $191.2 million compared to the $186.32 million average estimate based on two analysts. The reported number represents a change of -5.2% year over year.Net Sales- Orthopedic Surgery: $152.3 million versus the two-analyst average estimate of $150.93 million. The reported number represents a year-over-year change of +8.2%.Net Sales- Capital Products: $48.4 million versus the two-analyst average estimate of $50.42 million. The reported number represents a year-over-year change of +8.8%.View all Key Company Metrics for Conmed here>>>

Shares of Conmed have returned +35.2% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Key Takeaways CONMED's AirSeal is now FDA-cleared for 8 mm hex cannulas on the da Vinci 5 robotic platform.Joint testing with Intuitive Surgical supported compatibility across da Vinci X, Xi and 5 systems.AirSeal maintains pressure, clears smoke and supports low-pressure insufflation during robotic surgery. CONMED (CNMD - Free Report) recently announced that the FDA has expanded the indication for its AirSeal Robotic Solution to be used with Intuitive Surgical’s (ISRG - Free Report) 8 mm hex cannulas on the da Vinci 5 (dV5) robotic surgery platform. Previously approved for Intuitive Surgical’s 8 mm round cannulas, the solution is now compatible across the full portfolio of the da Vinci X, da Vinci Xi and da Vinci 5 robotic systems.

Management noted that the expanded indication was supported by extensive engineering and technical compatibility testing conducted jointly with Intuitive Surgical. The company remains focused on providing surgeons and hospitals with compatibility data and clear product communication, helping them deliver high-quality patient care.

The expanded indication brings greater clarity on the integration of the AirSeal Robotic Solution with the da Vinci 5 platform, supporting efficient and consistent surgical workflows while contributing to positive patient outcomes. Management also expressed confidence that this achievement strengthens the long-term growth potential of CONMED’s AirSeal portfolio.

Likely Trend of CNMD Stock Following the NewsFollowing the announcement, CNMD shares gained 0.3% at yesterday’s close. Year to date, the stock has risen 3.5% against the industry’s 2.2% decline. However, the S&P 500 has risen 9.3% in the same timeframe.

CONMED is well positioned to benefit from the expanded indication for its AirSeal Robotic Solution. Compatibility with the da Vinci 5 platform broadens the product’s addressable market and reinforces its value within robotic-assisted minimally invasive surgeries. As hospitals continue to adopt ISRG’s latest robotic platform and the company continues to expand in international markets, adoption of CONMED’s AirSeal is likely to be strengthened, which will drive growth for its surgical portfolio.

CNMD currently has a market capitalization of $1.26 billion.

Image Source: Zacks Investment Research

More on the NewsThe AirSeal Robotic Solution is an advanced insufflation system developed specifically for robotic-assisted minimally invasive surgery. It combines an AirSeal Cannula Cap with AirSeal and a bifurcated tube set to deliver stable pneumoperitoneum, continuous smoke evacuation and low-pressure insufflation through robotic ports, eliminating the need for an accessory port. Unlike conventional insufflation systems that replenish carbon dioxide only after pressure drops, AirSeal maintains pressure, improving visualization and minimizing interruptions during surgery.

Its three-lumen design provides CO2 insufflation, smoke evacuation and a regulated gas barrier that maintains consistent cavity pressure even during leaks or suction. By preserving visualization, minimizing pressure fluctuations and restoring pneumoperitoneum when disruptions occur, the system supports physiologic stability, enhances intraoperative efficiency and contributes to smoother patient recovery during minimally invasive robotic procedures.

The expanded indication strengthens AirSeal’s role in robotic surgery by enabling seamless integration with Intuitive Surgical’s latest system architecture while providing hospitals and surgeons with greater flexibility in using complementary technologies. Backed by more than 40 clinical studies, the system is designed to support low-pressure insufflation, helping improve patient outcomes, procedural efficiency and surgical performance.

Industry Prospects Favoring the MarketGoing by the data provided by Mordor Intelligence, the insufflation devices market is predicted to be valued at $3.28 billion in 2026 and is expected to witness a CAGR of 5.9% through 2031.

Factors like the growing adoption of minimally invasive surgeries, advancements in insufflation technology, rising volumes of bariatric and gynecologic procedures, integration with digital operating rooms, expanding ambulatory surgery infrastructure and a shift toward disposable insufflation consumables are boosting the market’s growth.

Other NewsCONMED recently appointed John E. Gallagher as its chief financial officer, effective July 15, 2026. He succeeds Todd Garner, who will remain associated with the company in an advisory role through Nov. 2, 2026. Gallagher brings nearly three decades of financial leadership experience across public healthcare and industrial companies, including Certara, Inc., Cue Health Inc. and Becton, Dickinson & Co.

In May, CONMED announced the appointment of seasoned healthcare executives Celine Martin and Jeff Mirviss to its board of directors, effective July 1, 2026. The move expands the board to nine members and strengthens governance with deep leadership expertise from Johnson & Johnson and Boston Scientific.

CNMD’s Zacks Rank & Key PicksCONMED currently carries a Zacks Rank #5 (Strong Sell).

Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

West Pharmaceutical reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.

Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.

Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.

CONMED Corporation (NYSE: CNMD) today announced that its [url="]AirSeal Robotic Solution[/url] is now indicated for use with Intuitive's 8 mm hex cannulas us

Posted by Defense World Staff on Jul 21st, 2026

Allspring Global Investments Holdings LLC grew its position in shares of CONMED Corporation (NYSE:CNMD – Free Report) by 39.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 582,733 shares of the company’s stock after buying an additional 166,301 shares during the quarter. Allspring Global Investments Holdings LLC owned 1.94% of CONMED worth $20,705,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Kestra Advisory Services LLC purchased a new stake in shares of CONMED during the 4th quarter valued at about $26,000. Kelleher Financial Advisors bought a new position in shares of CONMED in the 3rd quarter worth approximately $28,000. Aster Capital Management DIFC Ltd boosted its holdings in shares of CONMED by 409.2% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 723 shares of the company’s stock worth $29,000 after buying an additional 581 shares during the last quarter. Quarry LP boosted its holdings in shares of CONMED by 244.8% in the third quarter. Quarry LP now owns 869 shares of the company’s stock worth $41,000 after buying an additional 617 shares during the last quarter. Finally, Rockefeller Capital Management L.P. grew its position in CONMED by 48.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,043 shares of the company’s stock valued at $42,000 after buying an additional 341 shares during the period.

Analyst Ratings Changes Several research firms have weighed in on CNMD. Zacks Research downgraded shares of CONMED from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Bank of America restated an “underperform” rating and issued a $40.00 price objective on shares of CONMED in a research note on Monday, June 29th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of CONMED in a report on Thursday, June 4th. Wells Fargo & Company set a $39.00 target price on CONMED in a research report on Monday, July 13th. Finally, BMO Capital Markets initiated coverage on CONMED in a report on Wednesday, July 8th. They set a “market perform” rating and a $36.00 price target for the company. Five analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, CONMED currently has an average rating of “Reduce” and a consensus target price of $38.80.

Check Out Our Latest Stock Analysis on CNMD

CONMED Price Performance CNMD stock opened at $43.51 on Tuesday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.29. The company’s fifty day moving average price is $35.98 and its 200-day moving average price is $38.36. CONMED Corporation has a one year low of $31.44 and a one year high of $56.63. The company has a market capitalization of $1.31 billion, a PE ratio of 24.58, a price-to-earnings-growth ratio of 3.19 and a beta of 0.93.

CONMED (NYSE:CNMD – Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $0.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The company had revenue of $317.05 million for the quarter, compared to the consensus estimate of $310.64 million. CONMED had a net margin of 4.00% and a return on equity of 13.84%. CONMED’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.95 EPS. On average, equities analysts anticipate that CONMED Corporation will post 4.38 EPS for the current fiscal year.

CONMED Profile (Free Report)

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.

See Also Five stocks we like better than CONMED The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEThe New Germany Fund, Inc. $GF Shares Sold by Allspring Global Investments Holdings LLC

NEXT HEADLINE »Allspring Global Investments Holdings LLC Purchases 104,466 Shares of Kontoor Brands, Inc. $KTB

-

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results.

To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.

This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website: https://www.conmed.com/en/investor-relations. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

More News From CONMED Corporation

Back to Newsroom

Shares of CONMED Corporation (NYSE: CNMD - Get Free Report) have earned an average rating of "Reduce" from the eight analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven have issued a hold recommendation on the company. The average 12 month price

Key Takeaways CONMED growth is driven by AirSeal, Buffalo Filter, and BioBrace platforms, gaining adoption.CNMD benefits from supply-chain recovery, boosting orthopedic sales and product availability.CONMED expects margin gains from GI exit, despite tariff and revenue headwinds in 2026. CONMED Corporation (CNMD - Free Report) is well-positioned for growth on the back of rising adoption of its high-margin, differentiated platforms like AirSeal, Buffalo Filter and BioBrace. The company’s long-term prospects seem good as robotic procedure volume rises, coupled with the expanding penetration of Ambulatory Surgery Centers. Moreover, improving supply-chain bottlenecks should drive top- and bottom-line growth.

CONMED is facing tariff headwinds that are unfavorably impacting its earnings per share (EPS) and revenue expansion. Higher operating expense investments remain a concern.

Shares of this Zacks Rank #3 (Hold) company have lost 9.9% in the year-to-date period compared with the industry’s 3.3% decline and the S&P 500 Index’s 3.6% fall.

CONMED, a renowned global medical products manufacturer specializing in surgical instruments and devices, has a market capitalization of $1.06 billion. The company projects 5.2% earnings growth over the next five years.

The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.56%.

Image Source: Zacks Investment Research

Factors Favoring CNMD StockStrong Growth Drivers in High-Margin Segment: CONMED delivered a strong fourth-quarter fiscal 2025 performance, led by robust orthopedic growth, solid execution and continued expansion of its higher-margin platforms. Looking ahead to fiscal 2026, management plans to stay focused on three key growth drivers, AirSeal insufflation systems, Buffalo Filter and BioBrace, which offer favorable procedural growth and margin profiles. AirSeal remains significantly underpenetrated in traditional laparoscopy, currently used in just 6–7% of the more than 3 million annual U.S. procedures, leaving ample room for long-term expansion as adoption improves.

Buffalo Filter continues to benefit from a growing global smoke evacuation market exceeding $1 billion, supported by increasing regulatory mandates such as smoke-free operating room laws across multiple U.S. states, as well as adoption in Nordic countries and Canada. Meanwhile, BioBrace is gaining traction across more than 70 surgical applications, with new product innovations and ongoing clinical validation strengthening its adoption. Collectively, these platforms underscore CONMED’s strategy to prioritize R&D, commercial execution and capital allocation toward high-growth, high-margin opportunities.

Supply-Chain Normalization Boosting Orthopedics Recovery: Resolving the sports medicine supply-chain constraints remains a central operational priority entering fiscal 2026. During fiscal 2025, the company invested in additional planning capabilities, infrastructure, external operational expertise and leadership resources, including back-order levels and the number of affected SKUs declining to a three-year low by year-end.

This improvement enabled the orthopedics segment to return to stronger growth, with fourth-quarter orthopedic sales rising 12.1% in constant currency, reflecting both improving product availability and continued demand for key offerings such as BioBrace and other soft-tissue repair solutions.

Management’s near-term objective is to stabilize and scale supply processes to ensure consistent product availability, while the long-term objective is to build a more agile, data-driven, high-performance supply chain to support sustained innovation and above-market growth in the orthopedic portfolio over time.

Margin Improvement Initiatives and Capital Returns: Several structural actions underway are expected to strengthen profitability and shareholder returns beginning in fiscal 2026 and continuing thereafter. The strategic exit from the gastroenterology product lines is intended to concentrate resources on higher-growth, higher-margin businesses. It is expected to improve the company’s consolidated long-term gross margin profile by 80 basis points (bps) once the transition is completed.

For fiscal 2026, CONMED guided to an additional 50 to 100 bps of gross-margin expansion, driven by favorable product mix and cost improvements. The company suspended its dividend and authorized a $150 million share repurchase program, with management indicating that redeploying the prior dividend amount toward buybacks is expected to contribute 7 cents of EPS accretion in fiscal 2026, supporting ongoing capital-return priorities while maintaining flexibility to invest in innovation and growth initiatives.

Downsides of CNMD StockRevenue & EPS Headwinds From GI Exit and Tariffs: While CNMD is positioning itself for stronger long-term growth and profitability, near-term challenges tied to strategic portfolio changes and external cost pressures remain. Management expects fiscal 2026 revenue growth to be moderate, with constant-currency organic growth of 4.5% to 6%, impacted by the shift away from lower-priority product lines. U.S. general surgery performance has also been affected by portfolio rationalization, including the exit of select smaller products, reduced focus on OEM smoke-evacuation offerings and the broader exit from the gastroenterology business.

Adjusted EPS is projected to be in the range of $4.30 to $4.45, down from $4.59 in fiscal 2025, reflecting a 45–50 cent hit from the GI exit and an additional 30–35 cent drag from tariff-related costs. Despite these pressures, management views the GI exit as a strategic move to enhance long-term margins and prioritize higher-growth areas.

Rising Operating Expense Investments: Operating expenses are anticipated to increase in fiscal 2026 as the company ramps up investments to drive its core growth platforms and strengthen its innovation pipeline. Adjusted SG&A expenses are expected to reach 38% to 38.5% of sales, influenced by lower revenues following the exit of the GI portfolio and higher commercial spending to support the expansion of key surgical and orthopedic businesses. Meanwhile, R&D spending is projected to rise to 4.5% to 5% of sales, marking an increase from previous years as CNMD allocates more resources toward product development, clinical research and technological advancements in areas such as robotic and laparoscopic surgery, smoke evacuation and soft-tissue repair.

Estimate TrendCONMED is witnessing a stable estimate revision trend for fiscal 2026. In the past 60 days, the Zacks Consensus Estimate for earnings has remained stable at $4.36 per share.

The Zacks Consensus Estimate for first-quarter fiscal 2026 revenues and EPS is pegged at $310.7 million and 82 cents, respectively, suggesting 3.3% and 13.7% declines from the year-ago reported numbers.

Stocks to ConsiderSome better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , GE HealthCare Technologies (GEHC - Free Report) and Cardinal Health (CAH - Free Report) .

Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.

GE HealthCare Technologies, currently carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.

GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.

Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.

CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.3% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2026.

First Quarter 2026 Highlights

Sales of $317.0 million decreased 1.3% year-over-year as reported and 2.9% in constant currency. Net sales growth was impacted by a $15.5 million decrease in sales from the exit of certain GI products. Domestic revenue decreased 5.8% year-over-year. Domestic sales growth was impacted by a $15.2 million decrease in sales from the exit of certain GI products. International revenue increased 4.7% year-over-year as reported and 1.0% in constant currency. International sales growth was impacted by a $0.3 million decrease in sales from the exit of certain GI products. Diluted net earnings per share (GAAP) were $0.45, compared to diluted net earnings per share (GAAP) of $0.19 in the first quarter of 2025. Adjusted diluted net earnings per share(1) were $0.89, compared to adjusted diluted net earnings per share of $0.95 in the first quarter of 2025. “Our 2025 momentum continued in the first quarter as we delivered revenue and adjusted earnings ahead of our expectations,” said Patrick J. Beyer, CONMED’s President and Chief Executive Officer. “We continue to concentrate our resources and investment on our higher-growth, higher-margin areas: minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.”

2026 Outlook

Based on the Company’s first quarter performance, management is raising its outlook for full-year 2026 organic revenue growth on a constant currency basis. The Company now expects year-over-year organic constant currency revenue growth, which excludes gastroenterology product sales, of approximately 5.0% to 6.5% compared to the prior guidance range of 4.5% to 6.0%. Full-year 2026 reported revenue is now expected to be in the range of $1.350 billion to $1.375 billion, compared to prior guidance of $1.345 billion to $1.375 billion. The updated revenue outlook reflects an estimated 40 to 50 basis points of favorable foreign exchange impact, compared to the prior assumption of 0 to 50 basis points of favorable impact. This updated guidance also reflects an estimated $14.5 million to $17.5 million in revenue from gastroenterology products, reduced from the prior guidance of $21.0 million to $25.0 million due to the divestiture of the remaining gastroenterology portfolio.

The Company continues to expect full-year adjusted diluted net earnings per share(2) in the range of $4.30 to $4.45. The reaffirmed outlook reflects stronger underlying operating performance, largely offset by higher-than-previously anticipated interest expense due to the planned refinancing of the Company's debt during 2026.

Supplemental Financial Disclosures

(1) A reconciliation of reported diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.

(2) Information reconciling forward-looking adjusted diluted net earnings per share to the comparable GAAP financial measures is unavailable to the company without unreasonable effort, as discussed below.

Conference Call

The Company’s management will host a conference call today at 4:30 p.m. ET to discuss its first quarter 2026 results.

To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.

This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

Consolidated Condensed Statements of Income

(in thousands except per share amounts, unaudited)

Three Months Ended

March 31,

2026

2025

Net sales

$

317,046

$

321,256

Cost of sales

133,599

143,504

Gross profit

183,447

177,752

% of sales

57.9

%

55.3

%

Selling & administrative expense

141,699

148,847

Research & development expense

16,333

12,947

Income from operations

25,415

15,958

% of sales

8.0

%

5.0

%

Interest expense

7,060

8,286

Income before income taxes

18,355

7,672

Provision for income taxes

4,527

1,636

Net income

$

13,828

$

6,036

Basic EPS

$

0.45

$

0.19

Diluted EPS

0.45

0.19

Basic shares

30,588

30,973

Diluted shares

30,621

31,151

Sales Summary

(in millions, unaudited)

Three Months Ended March 31,

% Change

Domestic

International

2026

2025

As

Reported

Impact of

Foreign

Currency

Constant

Currency

As

Reported

As

Reported

Impact of

Foreign

Currency

Constant

Currency

Orthopedic Surgery

$

147.7

$

138.3

6.8

%

-2.3

%

4.5

%

5.5

%

7.6

%

-3.7

%

3.9

%

General Surgery

169.3

183.0

-7.4

%

-1.1

%

-8.5

%

-10.4

%

0.1

%

-3.9

%

-3.8

%

$

317.0

$

321.3

-1.3

%

-1.6

%

-2.9

%

-5.8

%

4.7

%

-3.7

%

1.0

%

Single-use Products

$

270.0

$

276.3

-2.3

%

-1.6

%

-3.9

%

-8.1

%

6.2

%

-4.0

%

2.2

%

Capital Products

47.0

45.0

4.6

%

-1.5

%

3.1

%

12.4

%

-2.0

%

-2.8

%

-4.8

%

$

317.0

$

321.3

-1.3

%

-1.6

%

-2.9

%

-5.8

%

4.7

%

-3.7

%

1.0

%

Domestic

$

173.0

$

183.8

-5.8

%

0.0

%

-5.8

%

International

144.0

137.5

4.7

%

-3.7

%

1.0

%

$

317.0

$

321.3

-1.3

%

-1.6

%

-2.9

%

Reconciliation of Reported Net Income to Adjusted Net Income

(in thousands, except per share amounts, unaudited)

Three Months Ended March 31, 2026

Gross Profit

Selling & Administrative Expense

Research & Development Expense

Operating Income

Interest Expense

Tax Expense

Effective Tax Rate

Net Income

Diluted EPS

As reported

$

183,447

$

141,699

$

16,333

$

25,415

$

7,060

$

4,527

24.7

%

$

13,828

$

0.45

% of sales

57.9

%

44.7

%

5.2

%

8.0

%

Operational optimization costs(1)

379

(7,526

)

-

7,905

-

1,801

6,104

Executive transition costs(2)

-

(3,342

)

-

3,342

-

761

2,581

EU medical device regulations(3)

-

-

(1,167

)

1,167

-

266

901

Contingent consideration fair value adjustments(4)

-

(722

)

-

722

-

164

558

Termination of distribution agreement(5)

(1,864

)

-

-

(1,864

)

-

(425

)

(1,439

)

Gain on sale of product line(6)

-

3,916

-

(3,916

)

-

(892

)

(3,024

)

$

181,962

$

134,025

$

15,166

$

32,771

$

7,060

$

6,202

$

19,509

Adjusted gross profit %

57.4

%

Amortization(7)

$

1,500

(7,261

)

-

8,761

(1,276

)

2,442

7,595

As adjusted

$

126,764

$

15,166

$

41,532

$

5,784

$

8,644

24.2

%

$

27,104

$

0.89

% of sales

40.0

%

4.8

%

13.1

%

Three Months Ended March 31, 2025

Gross Profit

Selling & Administrative Expense

Research & Development Expense

Operating Income

Interest Expense

Tax Expense

Effective Tax Rate

Net Income

Diluted EPS

As reported

$

177,752

$

148,847

$

12,947

$

15,958

$

8,286

$

1,636

21.3

%

$

6,036

$

0.19

% of sales

55.3

%

46.3

%

4.0

%

5.0

%

Operational optimization costs(1)

3,410

(490

)

-

3,900

-

901

2,999

Executive transition costs(2)

-

(12,165

)

-

12,165

-

2,812

9,353

Contingent consideration fair value adjustments(4)

-

(3,962

)

-

3,962

-

916

3,046

Gain on sale of product line(6)

-

354

-

(354

)

-

(82

)

(272

)

Legal matters(8)

-

(1,037

)

-

1,037

-

240

797

$

181,162

$

131,547

$

12,947

$

36,668

$

8,286

$

6,423

$

21,959

Adjusted gross profit %

56.4

%

Amortization(7)

$

1,500

(7,172

)

-

8,672

(1,443

)

2,455

7,660

As adjusted

$

124,375

$

12,947

$

45,340

$

6,843

$

8,878

23.1

%

$

29,619

$

0.95

% of sales

38.7

%

4.0

%

14.1

%

Reconciliation of Reported Net Income to EBITDA & Adjusted EBITDA

(in thousands, unaudited)

Three Months Ended

March 31,

2026

2025

Net income

$

13,828

$

6,036

Provision for income taxes

4,527

1,636

Interest expense

7,060

8,286

Depreciation

4,174

4,235

Amortization

14,663

14,018

EBITDA

$

44,252

$

34,211

Stock based compensation

4,783

6,381

Operational optimization costs

7,905

3,900

Executive transition costs

3,342

12,165

EU medical device regulations

1,167

-

Contingent consideration fair value adjustments

722

3,962

Termination of distribution agreement

(1,864

)

-

Gain on sale of product line

(3,916

)

(354

)

Legal matters

-

1,037

Adjusted EBITDA

$

56,391

$

61,302

EBITDA Margin

EBITDA

14.0

%

10.6

%

Adjusted EBITDA

17.8

%

19.1

%

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025 and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

Supplemental Information - Reconciliation of GAAP to Non-GAAP Financial Measures

The Company supplements the reporting of its financial information determined under generally accepted accounting principles in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted research and development expense; adjusted operating income; adjusted interest expense; adjusted income tax expense; adjusted effective income tax rate; adjusted net income and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial results and assessing its prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of its operations because they exclude items that may not be indicative of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company’s underlying business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company’s cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial measures.

Net sales on a constant currency basis is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, cost of sales, selling and administrative expenses, research and development expense, operating income, interest expense, income tax expense, effective income tax rate, net income and diluted net earnings per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures above, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.

We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted diluted net earnings per share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our consolidated condensed statements of income.

For the quarter ended March 2026, Conmed (CNMD - Free Report) reported revenue of $317.05 million, down 1.3% over the same period last year. EPS came in at $0.89, compared to $0.95 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $310.7 million, representing a surprise of +2.04%. The company delivered an EPS surprise of +8.98%, with the consensus EPS estimate being $0.82.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Conmed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Geographic Revenue- International: $144 million versus the two-analyst average estimate of $137.8 million. The reported number represents a year-over-year change of +4.7%.Geographic Revenue- Domestic: $173 million versus $172.91 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -5.9% change.Net Sales- Single-use Products: $270 million versus $266.61 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2.3% change.Net Sales- General Surgery: $169.3 million compared to the $170.48 million average estimate based on two analysts. The reported number represents a change of -7.5% year over year.Net Sales- Orthopedic Surgery: $147.7 million compared to the $140.22 million average estimate based on two analysts. The reported number represents a change of +6.8% year over year.Net Sales- Capital Products: $47 million compared to the $44.09 million average estimate based on two analysts. The reported number represents a change of +4.4% year over year.View all Key Company Metrics for Conmed here>>>

Shares of Conmed have returned +4% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Key Takeaways CONMED beat Q1 EPS and revenue estimates, though sales dipped 1.3% year over year.CNMD raised its 2026 organic CER revenue growth outlook to 5-6.5% on stronger execution.CNMD saw orthopedic growth offset by GI product exit, which hurt general surgery sales. CONMED Corporation (CNMD - Free Report) posted adjusted earnings per share (EPS) of 89 cents for the first quarter of 2026, down 6.3% year over year. The figure beat the Zacks Consensus Estimate by 8.5%.

The adjustments include costs related to legal matters and contingent consideration fair value adjustments, among others.

GAAP EPS for the quarter was 45 cents, up 136.8% from the year-ago period’s EPS of 19 cents.

CNMD’s Revenues in DetailCONMED registered revenues of $317 million in the first quarter, down 1.3% year over year on a reported basis. The figure beat the Zacks Consensus Estimate by 2%.

At the constant exchange rate (CER), revenues were up 2.9% year over year.

Per management, the top line was hurt by a $15.5 million decrease in sales from the exit of certain GI products.

CONMED’s Segmental DetailsCNMD derived its revenues from two product lines — Orthopedic Surgery and General Surgery.

Orthopedic Surgery revenues in the fourth quarter totaled $147.7 million, up 6.8% and 4.5% year over year on a reported basis and at CER, respectively.

The U.S. Orthopedic sales grew 5.5%. Internationally, orthopedic sales increased 7.6% and 3.9% on a reported basis and at CER, respectively.

General Surgery revenues were $169.3 million, down 7.4% on a reported basis and 8.5% at CER year over year.

U.S. General Surgery sales declined 10.4%, while internationally General Surgery sales increased 0.1% but declined 3.8% on a reported basis and at CER, respectively.

The decline in the United States was due to a loss of $15.2 million in sales due to the exit of certain GI products.

CNMD’s Geographical ResultsDomestic revenues in the first quarter totaled $173 million, down 5.8% on a reported basis year over year.

International revenues in the first quarter amounted to $144 million, up 4.7% on a reported basis and 1% at CER year over year.

CONMED’s Margin AnalysisIn the quarter under review, CNMD’s adjusted gross profit increased 0.4% year over year to $181.9 million. The gross margin expanded 100 basis points (bps) to 57.4%.

Selling & administrative expenses decreased 4.8% year over year to $141.7 million. Research and development expenses rose 26.2% to $16.3 million. Total operating expenses of $158 million decreased 2.3% on a year-over-year basis.

Total adjusted operating profit totaled $32.8 million, reflecting a 10.6% decrease from the year-ago quarter. The operating margin in the first quarter contracted 100 bps to 13.1%.

CNMD’s Financial PositionThe company exited the reported quarter with cash and cash equivalents of $35 million compared with $40.8 million a year ago.

Cumulative net cash provided by operating activities at the end of first-quarter 2026 was $13.5 million compared with $41.5 million a year ago.

CONMED’s GuidanceCNMD has updated its outlook for 2026.

For 2026, total reported revenues are expected to be in the range of $1,350 million-$1,375 million compared with previous guidance of $1,345 million-$1,375 million. The Zacks Consensus Estimate is pegged at $1.36 billion.

Organic CER revenues are expected to lie between $1,331.2 million and $1,350.1 million, reflecting organic CER growth of 5-6.5% over the comparable 2025 period. The company previously expected Organic CER revenues of $1,324 million to $1,344 million.

The company continues to expect adjusted EPS for 2026 in the range of $4.30-$4.45. The Zacks Consensus Estimate is pegged at $4.36.

CONMED expects revenues to be in the range of $336 million-$340 million for the second quarter. The Zacks Consensus Estimate is pegged at $310.7 million.

Our Take on CNMDCONMED exited the first quarter of 2026 with better-than-expected results. CONMED’s results highlight a strategic reset that should underpin performance through the remainder of 2026. The divestiture of its gastroenterology business sharpens focus on higher-growth, higher-margin segments, namely AirSeal, Buffalo Filter and BioBrace. These platforms offer durable tailwinds: AirSeal benefits from rising robotic and laparoscopic procedure volumes and a large installed base, while Buffalo Filter is supported by increasing smoke-evacuation legislation and international adoption. BioBrace continues to gain traction as a differentiated orthopedic solution, with expanding clinical validation and surgeon adoption driving sustained growth.

Operationally, improving supply chain reliability is enabling the orthopedic segment to return to consistent mid-single-digit growth, with further acceleration expected as capacity expands. Additionally, raised organic growth guidance (5–6.5%) reflects improving business momentum and stronger execution.

However, challenges remain. The exit of GI creates a near-term revenue and earnings headwind, while OEM smoke products continue to weigh on general surgery performance. Inflationary pressures on input costs and higher interest expense from debt refinancing could also constrain margins. Despite these factors, CONMED’s focused portfolio and strengthening execution position it for steady growth in 2026.

CONMED’s Zacks Rank & Stocks to ConsiderCNMD currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Phibro Animal Health (PAHC - Free Report) andCardinal Health (CAH - Free Report) . While Globus Medical sports a Zacks Rank #1 (Strong Buy), Phibro Animal Health and Cardinal Health carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Globus Medical shares have gained 4% in the year-to-date period. Estimates for the company’s first-quarter 2026 EPS have increased 1 cent to 90 cents in the past 30 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 18.79%. In the last reported quarter, it posted an earnings surprise of 20.75%.

Estimates for Phibro Animal Health’s third-quarter fiscal 2026 EPS have remained constant at 72 cents in the past 30 days. Shares of the company have risen 45.3% in the year-to-date period against the industry’s 18.8% decline. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20.15%. In the last reported quarter, it delivered an earnings surprise of 26.09%.

Cardinal Health shares have remained flat in the year-to-date period. Estimates for the company’s third-quarter 2026 EPS have decreased 1 cent to $2.80 in the past 30 days. CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 9.30%. In the last reported quarter, it posted an earnings surprise of 10.04%.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (“Board”), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total of nine directors.

“My fellow directors and I are delighted to welcome Celine Martin and Jeff Mirviss to the Board, both highly accomplished leaders with extensive experience developed at two of the largest companies in the healthcare industry,” said LaVerne Council, Chair of CONMED’s Board of Directors. “Celine joins our Board following a 30-year career at Johnson & Johnson, with deep global leadership experience in MedTech and a track record of driving innovation and growth. Likewise, Jeff possesses nearly 30 years of experience at Boston Scientific, where he led complex, global medical device businesses with operational and commercial excellence. Their insight and expertise will be invaluable to the Board as we advance CONMED’s long‑term strategy.”

“Celine and Jeff are outstanding additions to the Board,” said Patrick Beyer, President and Chief Executive Officer of CONMED. “Celine’s global strategic leadership and experience scaling high growth medical technology businesses, combined with Jeff’s expertise in portfolio leadership and execution across large, global organizations, will strengthen our governance and support our continued focus on delivering long‑term value for patients, customers, and shareholders.”

Over three decades at Johnson & Johnson, both in the U.S. and internationally, Ms. Martin played a vital role in advancing the ambition of J&J MedTech, developing new categories and advancing standard of care for atrial fibrillation, stroke, and minimally invasive surgery. Most recently, she served as Company Group Chairman leading the Cardiovascular & Specialty Solutions (“CSS”) Group from 2022 to 2025. As a member of the J&J MedTech leadership team, she ran a diverse portfolio of high growth businesses including Electrophysiology, Neurovascular Intervention, Ear Nose and Throat, and Breast Aesthetics. Before that, Ms. Martin led the Ethicon Endo Surgery business where she was instrumental in establishing the Robotic and Digital Surgery portfolio foundations. Ms. Martin holds an MBA from Wake Forest University and a graduate degree in marketing from Normandy Business School. Ms. Martin also serves on the Board of Directors at H.B. Fuller.

Mr. Mirviss brings more than 35 years of healthcare industry leadership experience. Most recently, he served as Executive Vice President and Global President of Peripheral Interventions at Boston Scientific from 2020 to 2025, where he led a multi-billion dollar global business focused on therapies for vascular disease and cancer. In this role, he also had leadership responsibility for the Company’s Latin America and Canada regions, as well as its Government Affairs function. Previously, Mr. Mirviss served as Senior Vice President and Global President of Peripheral Interventions from 2013 to 2020, and as Global President of Peripheral Interventions from 2011 to 2013. Prior to these roles, Mr. Mirviss held positions of increasing responsibility at Boston Scientific, including Group Vice President of Global Marketing for the Company’s Cardiology, Rhythm and Vascular businesses. Mr. Mirviss holds a B.I.S. in Marketing from the University of Minnesota and an MBA from the University of St. Thomas.

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

Key Takeaways Cardinal Health's Other Growth Businesses revenues rose 34% to $1.7 billion in fiscal Q3.CAH saw NPHS growth fueled by theranostics demand and At-Home Solutions expansion.CAH's OptiFreight revenues rose nearly 20%, boosting higher-margin growth exposure. Cardinal Health’s (CAH - Free Report) fiscal third-quarter results suggest that the company’s “Other Growth Businesses” are evolving from complementary assets into a meaningful profit engine, underscoring management’s strategy to diversify beyond its traditionally low-margin pharmaceutical distribution business.

In the third quarter of fiscal 2026, revenues from the segment surged 34% to $1.7 billion, while segment profit climbed at an even faster rate of 52%, highlighting the increasing earnings leverage of these higher-margin operations.

The momentum was broad-based, with strength coming from Nuclear and Precision Health Solutions (NPHS), At-Home Solutions and OptiFreight Logistics. NPHS continued to benefit from rapid adoption of theranostics, where revenues gained more than 30%, supported by Cardinal Health’s investments in isotope production capabilities and rising demand for targeted cancer therapies. Management emphasized growing engagement with pharmaceutical innovators, which includes the Actinium-225 platform that is already supporting more than 15 clinical trials globally.

At-Home Solutions is benefiting from the secular shift of healthcare services toward home-based care. Demand remained strong, aided by the successful integration of the Advanced Diabetes Supply (ADS) acquisition. Cardinal Health has now onboarded nearly 500,000 new patients and about 1,000 employees. The company is also migrating ADS volumes into its distribution centers, creating scale efficiencies and a stronger chronic-care platform. The business is also generating synergies with pharma through its ContinuCare Pathway program, which now serves 165,000 patients.

OptiFreight Logistics added another layer of growth, with revenues increasing nearly 20%, reflecting rising demand for cost-efficient healthcare logistics solutions. Together, these businesses are not only diversifying Cardinal Health’s revenue mix but also expanding exposure to faster-growing, higher-margin healthcare niches — potentially making them an increasingly important driver of long-term profitability.

Peer UpdateAlign Technology’s (ALGN - Free Report) future growth appears increasingly tied to deeper penetration of digital orthodontics and improved operating leverage. In the first quarter of 2026, the company reported record clear aligner shipments of 686,000 cases, supported by double-digit growth in international markets, especially APAC, EMEA and Latin America, while North America stabilized.

Future demand drivers for ALGN include expanding adoption among teens and children through products such as Invisalign First and Palatal Expander. Apart from product adoption, growing DSO partnerships, and financing initiatives are improving affordability and case conversion. Align Technology’s profitability is likely to be driven by AI-enabled treatment planning, lower refinement rates, operational efficiencies and higher-margin product configurations requiring fewer aligners, supporting sustained margin expansion.

CONMED’s (CNMD - Free Report) long-term growth and profitability outlook is likely to be driven by its focused portfolio strategy and higher-margin surgical platforms. Following the strategic divestiture of its gastroenterology business, management is concentrating resources on AirSeal, Buffalo Filter and BioBrace, which target attractive growth categories in the healthcare segment.

AirSeal should benefit from increasing robotic and laparoscopic surgeries, where penetration is still low. The U.S. laparoscopic procedures exceed 3 million annually, representing significant growth opportunity. Buffalo Filter has a favorable tailwind from expanding smoke-free operating room legislation, while BioBrace adoption continues to strengthen as surgeons embrace biologic soft-tissue repair solutions. Improving supply-chain reliability and a richer product mix should also support margin expansion and profit recovery.

CAH’s Price Performance, Valuation and EstimatesShares of CAH have lost 2.4% so far this year compared with the industry’s 8.2% decline.

Image Source: Zacks Investment Research

From a valuation standpoint, Cardinal Health trades at a forward price-to-earnings ratio of 16.98, above the industry average. It is also higher than its five-year median of 13.72. CAH carries a Value Score of A.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Cardinal Health’s fiscal 2026 earnings implies a 30.1% rise from the year-ago period’s level, followed by 11.4% expected growth in fiscal 2027.

Image Source: Zacks Investment Research

The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways CONMED exited its GI portfolio to focus on higher-growth platforms with stronger margin potential.AirSeal's installed base tops 10,000 systems, with significant room for laparoscopic adoption.BioBrace gains traction in soft tissue repair, backed by growing clinical evidence and studies. CONMED Corporation (CNMD - Free Report) is well-positioned for growth on the back of rising adoption of its high-margin, differentiated platforms like AirSeal, Buffalo Filter and BioBrace. The company’s long-term prospects seem good as robotic procedure volume rises, coupled with the expanding penetration of Ambulatory Surgery Centers. Moreover, improving supply-chain bottlenecks should drive top- and bottom-line growth.

CONMED is facing tariff headwinds that are unfavorably impacting its earnings per share (EPS) and revenue expansion. Higher operating expense investments remain a concern.

Shares of this Zacks Rank #3 (Hold) company have lost 12.1% in the year-to-date period, underperforming the industry’s 9.2% decline and the S&P 500 Index’s 11.1% return.

Image Source: Zacks Investment Research

CONMED, a renowned global medical products manufacturer specializing in surgical instruments and devices, has a market capitalization of $1.07 billion. The company projects 5.1% earnings growth over the next five years.

The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 5.38%.

Factors Favoring CNMD StockStrategic Portfolio Simplification Should Improve Growth and Margin Quality: CONMED’s decision to fully exit its gastroenterology (GI) product portfolio represents a significant strategic shift toward higher-growth and higher-margin businesses. Management emphasized that the divestiture allows the company to redirect capital, commercial resources and management attention toward AirSeal, Buffalo Filter and BioBrace — three platforms with stronger competitive positioning and better long-term economics. While the GI business historically contributed to revenue generation, it carried lower strategic relevance and diluted growth rates. By concentrating investments on minimally invasive surgery, smoke evacuation and orthopedic soft tissue repair, CONMED is creating a more focused portfolio that should support faster organic growth, improved margin expansion and a clearer investment narrative over the next several years.

AirSeal Continues to Benefit From Multiple Structural Growth Drivers: AirSeal remains one of CONMED’s most important growth assets, supported by both robotic surgery expansion and underpenetrated laparoscopic procedures. The company now has an installed base exceeding 10,000 systems globally, providing recurring disposable revenues and strong surgeon familiarity. Beyond robotics, management highlighted that AirSeal is currently utilized in only 6-7% of the more than three million laparoscopic procedures performed annually in the United States, suggesting a substantial runway for adoption. CONMED placed more than 50% additional AirSeal units into the market compared with the prior-year quarter, which should support future disposable utilization. This combination of installed-base growth and low market penetration creates an attractive long-term growth profile.

BioBrace Emerging as a Differentiated Orthopedic Growth Platform: BioBrace continues to gain traction as a next-generation soft tissue repair technology and is increasingly becoming a cornerstone of CONMED’s orthopedic strategy. The implant uniquely combines structural reinforcement with biologic healing support, differentiating it from competing repair solutions. Management noted that surgeons are expanding the use of BioBrace across both primary repairs and more complex procedures, with more than 30 published studies strengthening clinical confidence. Additionally, the ongoing 268-patient randomized controlled trial could provide a powerful clinical catalyst. The trial is expected to complete enrollment in 2026. As orthopedic surgeons increasingly prioritize biologic augmentation and durability of repair outcomes, BioBrace appears well-positioned to capture share within a large and growing sports medicine market.

Supply Chain Recovery Creating Opportunity for Market Share Recapture: After several years of operational challenges, CONMED appears to be making meaningful progress in restoring supply chain reliability. Management stated that improvements achieved in late 2025 have been sustained through the first quarter of 2026, enabling orthopedic sales teams to become more proactive with customers rather than focusing primarily on product availability issues. Orthopedics delivered mid-single-digit growth for the third consecutive quarter, supported by improved service levels and stronger execution. Management believes customer relationships remained intact during supply disruptions, creating an opportunity to gradually regain lost business as contracts renew. A more reliable supply chain should not only support revenue growth but also improve operational leverage and customer confidence over time.

Downsides of CNMD StockRising Debt Costs Could Become a Meaningful Earnings Headwind: CONMED faces increasing financing costs as it refinances upcoming debt obligations. Management indicated that replacing expected convertible financing with traditional bank debt will increase interest expense and create at least a 10-cent EPS headwind in 2026, with potential implications extending into 2027. Long-term debt stood at approximately $860 million, while leverage remains around 3.1x EBITDA. Although management emphasized strong banking relationships and liquidity access, higher borrowing costs reduce financial flexibility and may limit future capital deployment options. In an environment where medtech valuations remain depressed and interest rates elevated, refinancing risk could continue to weigh on earnings growth and shareholder returns.

Smoke Evacuation Growth Still Being Offset by Weak OEM Performance: Buffalo Filter remains a compelling long-term opportunity, particularly as more states adopt smoke-free operating room legislation. However, near-term growth continues to be constrained by weakness in the OEM smoke evacuation business, which management described as a “meaningful headwind” during the first quarter. The OEM portion remains volatile and lumpy, creating quarterly revenue fluctuations that can mask the stronger performance of the direct smoke business. While management expects direct smoke evacuation to increasingly dominate the revenue mix over time, the transition period could create uneven growth patterns. Investors may therefore continue to see variability in reported performance despite favorable long-term legislative and clinical adoption trends.

Inflationary and Cost Pressures Could Limit Margin Expansion: Management acknowledged ongoing cost inflation across several key inputs, including oil-based materials, precious metals and medical device components. Although CONMED currently believes these pressures are incorporated into guidance and manageable through supplier negotiations and pricing actions, the company remains vulnerable to broader macroeconomic and geopolitical developments. Gross margin improved 100 basis points in the first quarter, aided by a favorable product mix, but sustaining that improvement may become increasingly difficult if commodity inflation accelerates or supply chain costs rise further. Given the company’s ongoing investment cycle and refinancing-related interest expense pressures, any inability to offset cost inflation could constrain future margin expansion and earnings growth.

Estimate TrendCONMED is witnessing a stable estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for earnings has improved 2 cents to $4.38 per share.

The Zacks Consensus Estimate for second-quarter fiscal 2026 revenues and EPS is pegged at $337.2 million and $1.10, suggesting 1.5% and 4.4% declines, respectively, from the year-ago reported numbers.

Stocks to ConsiderSome better-ranked stocks from the broader medical space are Pacific Biosciences of California (PACB - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .

Globus Medical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 adjusted EPS of $1.12, which outpaced the Zacks Consensus Estimate by 21.7%. Revenues of $760 million surpassed the Zacks Consensus Estimate by 4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% appreciation. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.26%.

Pacific Biosciences of California, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 29.4%. Revenues of $37 million missed the Zacks Consensus Estimate by 9.3%.

PACB’s earnings are estimated to improve at a rate of 22.6% compared with the industry’s 13.3% growth in 2026. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 29.76%.

Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which beat the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.

BDSX has an estimated earnings growth rate of 36% for 2026 compared with the industry’s 12.5% return. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.56%.